Laboratory Corporation of America Holdings expanded its blood biomarker test portfolio for Alzheimer’s disease, making its pTau217 test available by prescription in the U.S. as well as for research globally. The standalone test can also be used in monitoring patients undergoing treatment for the neurodegenerative disease.

A Massachusetts Institute of Technology-led team has identified distinct midbrain circuits that contributed to both motor and psychiatric symptoms of Parkinson's disease in animal models. Activating the circuits could reverse both types of symptoms.